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Material and Methods: Using the institutional databases of 3 
large UK Cancer Centres (Belfast, Glasgow and Leeds), 
patients who had curative intent thoracic radiation for NSCLC 
during 2010 were identified. Baseline demographics were 
collated, along with details of initial irradiation, relapse and 
subsequent management. Summary statistics were generated 
detailing the incidence of re-irradiation, treatment intent of 
re-irradiation and dose fractionation used. 
 
Results: In total, 351 patients were identified who had 
curative intent radiation. Of these, 188 (54%) relapsed, 60 
with local relapse only. Eleven patients (18% of those with 
local relapse) received palliative re-irradiation to thorax for 
specific symptoms, with fractionation schemes including 
8Gy/1 fraction, 16Gy/2 fractions, 20Gy/5 fractions and 
30Gy/10 fractions. Four patients (6%) received radical re-
irradiation with curative intent using 55Gy/20 fractions (3 
patients) or 55Gy/5 fractions (1 patient). Thirty-five patients 
(58%) had no treatment at relapse and most were categorised 
unfit. Four patients had salvage radical surgery. The 
remainder had systemic therapy or palliative supportive care. 
Median time between initial radiotherapy and local relapse 
was 13.5 months (3-49 months). Median time from initial 
radiation and re-irradiation was 24 months (6-41 months). No 
excessive radiation related toxicity was reported. 
 
Conclusion: In this selected cohort, re-irradiation is used 
routinely for patients with NSCLC, both with palliative and 
curative intent for local failure following radical thoracic 
radiotherapy. Further investigation of re-irradiation is 
warranted to assess toxicity, optimise techniques used and 
improve patient accessibility. 
 
EP-1239  
Clinical outcome of SBRT of central, apical or paracostal 
tumors in the lung, a retrospective study 
C. Kristiansen
1Department of Clinical Oncology, Odense University 
Hospital, Odense, Denmark 
1, S.S. Jeppesen1,2, M. Nielsen3, T.B. Nielsen3, 
T. Schytte1, O. Hansen1,2 
2Instiute of Clinical Research, University of Southern 
Denmark, Odense, Denmark 
3Laboratory of Clinical Research, Odense University Hosptial, 
Odense, Denmark 
 
Purpose or Objective: Stereotactic body radiotherapy (SBRT) 
of lung tumors gives excellent local control but with higher 
rates of toxicity for organs at risk located close to the tumor. 
Treating centrally located tumors with SBRT with 3 fractions 
increases the risk of severe side effects especially when 
located near the proximal bronchial tree (PBT) known from 
earlier studies. We aimed to evaluate our current practice 
using 56 Gy in 8 fractions for tumors located centrally in the 
lung or close to other organs at risk (OAR) located more 
peripherally in the lung. 
 
Material and Methods: Medically inoperable patients treated 
with 56 Gy in 8 fractions from the 1th of June 2012 until the 
1th of September 2014 were reviewed and analyzed. The 
patients were deemed unfit for SBRT in 3 fractions or 
normally fractionated radiotherapy. For three patients this 
treatment was part of the Nordic Hilus Study 
 
Results: Fifty patients were treated with a median follow up 
of 23.7 months (12.5-38.4). For baseline characteristics, see 
table 1. Not all tumors were centrally located; some tumors 
were close to columna, the apex of the lung or invaded the 
thoracic wall. Six patients had a locally recurrence (12%) and 
15 distant recurrence (30%). Twenty-seven patients had died 
by the end of data analysis. Thirteen patients died of 
recurrent lung cancer. One patient died of another cancer. 
Two patients died suddenly without obvious cause. Eight 
patients died of other reasons, primary due to infections 
and/or known heart disease. Three patients died of 
hemoptysis probably due to bleeding from the main 
bronchus. Only one of these patients had an autopsy. This 
patient was re-irradiated with 30 Gy in 10 fractions because 
of recurrence overlapping the initial site. The 1 year survival 
was 76%, 2 year survival 41% and the 3 year survival was 38%. 
The median overall survival was 21.1 months (3.1 – 37.0). 
 
 
 
Conclusion: SBRT with 56 Gy in 8 fractions for lung cancer in 
relation to OAR are tolerable with an acceptable local 
recurrence of 12%. The three patients who died of 
hemoptysis had their tumor located close to the main 
bronchus. Treatment of SBRT close to the PBT is known to 
cause damage to the bronchus. Due to the retrospective 
format of the trial some side-effects may be underreported. 
It is challenging to treat tumors close to organs at risk and in 
particularly the bronchial three with a dose to achieve local 
control and without harming the PBT or close to OAR. 
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Purpose or Objective: Technique and indication of 
stereotactic fractionated radiotherapy (SBRT) has emerged 
rapidly during the last decade. Delineation, dose 
specification and constraints have been adjusted to updated 
evidence. Retrospective Quality Assurance (QA) of available 
prospective data was performed in order to reconsider 
recommendations and might reveal important insights for 
future treatment strategies. 
 
Material and Methods: Within a prospective monocenter 
phase II study (STIPRE) 100 patients, elderly or unfit for 
surgery, have been treated with SBRT for 120 pulmonary 
lesions ≤5cm between 02/2011 and 12/2014. Applied doses 
were 3X12.5 Gy (85 lesions), 5X7Gy (30),7X5Gy (1) 4X6.5 Gy 
(1), 5X6.5 Gy (1), 8X7.5 Gy (1), 12X4.5 Gy (1), prescribed to 
60% isodose in all but 2 patients. Delineation of organs at risk 
(OARs) was requested, however not specified in a detailed 
way in the trial protocol. Applying a moderate dose no 
constraints were provided in the protocol but derived from 
the evidence available at that time. SBRT plans had been 
evaluated by at least two experienced radiation oncologists 
before treatment. Within the retrospective QA process of the 
trial we now evaluated the maximal dose applied to OARs and 
analyzed those data with respect to the dose constraints of 
the recently launched EORTC 22113-08113 Lungtech trial. If 
